Table 5.

The comparison of changes in the spirometry tests between the intervention and control groups.

Variable	Pomegranate (n = 32)	Placebo (n = 32)	P-value*
Mild severity
FEV1 (%)
Baseline	95.06 ± 14.48	93.75 ± 15.15	0.86
Endpoint (8 weeks)	98.56 ± 9.23	92.56 ± 13.49	0.22
Changes	3.50 ± 9.55	– 1.18 ± 17.89	0.17
P-value**	0.02	0.6
FVC (%)
Baseline	101.25 ± 11.27	99.88 ± 21.81	0.72
Endpoint (8 weeks)	101.81 ± 12.27	100.44 ± 15.81	0.95
Changes	0.56 ± 11.17	0.56 ± 15.00	0.65
P-value**	0.84	0.77
FEV1/FVC
Baseline	98.56 ± 9.94	99.06 ± 10.29	0.62
Endpoint (8 weeks)	104.00 ± 11.70	95.06 ± 13.89	0.05
Changes	5.43 ± 8.80	– 4.00 ± 9.34	0.008
P-value**	0.006	0.2
FEF25 − 75%
Baseline	77.38 ± 30.91	77.06 ± 19.48	0.66
Endpoint (8 weeks)	85.94 ± 36.59	75.06 ± 19.48	0.42
Changes	8.56 ± 14.61	−2.00 ± 22.71	0.11
P-value**	0.03	0.77
Moderate severity
FEV1 (%)
Baseline	79.94 ± 17.41	75.75 ± 15.90	0.66
Endpoint (8 weeks)	87.31 ± 14.92	80.69 ± 11.78	0.2
Changes	7.37 ± 17.79	4.93 ± 11.56	0.57
P-value**	0.03	0.11
FVC (%)
Baseline	85.94 ± 17.00	88.88 ± 14.69	0.47
Endpoint (8 weeks)	91.81 ± 16.40	91.31 ± 12.13	0.98
Changes	5.78 ± 16.18	2.43 ± 6.68	0.31
P-value**	0.08	0.22
FEV1/FVC
Baseline	93.75 ± 8.60	91.31 ± 15.85	0.47
Endpoint (8 weeks)	98.31 ± 5.30	93.81 ± 13.16	0.09
Changes	4.56 ± 6.83	2.50 ± 9.28	0.49
P-value**	0.02	0.28
FEF25 − 75%
Baseline	62.56 ± 29.12	62.25 ± 31.52	0.98
Endpoint (8 weeks)	70.75 ± 22.16	69.31 ± 32.32	0.47
Changes	8.18 ± 23.23	7.06 ± 2412	0.95
P-value**	0.14	0.11

Values are shown as mean ± standard deviation.

*Reported p-value to compare the research variables between the groups (Mann–Whitney U test or independent sample T-test).

**Reported p-value to evaluate the research variables within the groups (Wilcoxon test or paired T-test).